As a matter of fact, only a few types of cancer have been successfully treated with a single drug, e.g., imatinib in chronic myeloid leukemia [24], gefitinib (EGFR inhibitor) in mutant EGFR non-small cell lung cancer, and PLX4032 (BRAF inhibitor) in mutant BRAF melanoma [25,26,27,28]. Here, EGFR is linked to non-small cell lung carcinoma.